[go: up one dir, main page]

NO20083030L - 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer - Google Patents

1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer

Info

Publication number
NO20083030L
NO20083030L NO20083030A NO20083030A NO20083030L NO 20083030 L NO20083030 L NO 20083030L NO 20083030 A NO20083030 A NO 20083030A NO 20083030 A NO20083030 A NO 20083030A NO 20083030 L NO20083030 L NO 20083030L
Authority
NO
Norway
Prior art keywords
compounds
inhibitors
formula
treatment
insulin resistance
Prior art date
Application number
NO20083030A
Other languages
English (en)
Norwegian (no)
Inventor
Gary Mark Coppola
Travis Mathew Stams
Sidney Wolf Topiol
David Barnes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37903424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083030(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20083030L publication Critical patent/NO20083030L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
NO20083030A 2005-12-08 2008-07-04 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer NO20083030L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74849205P 2005-12-08 2005-12-08
PCT/US2006/046542 WO2007067612A1 (en) 2005-12-08 2006-12-06 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors

Publications (1)

Publication Number Publication Date
NO20083030L true NO20083030L (no) 2008-08-28

Family

ID=37903424

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083030A NO20083030L (no) 2005-12-08 2008-07-04 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer

Country Status (23)

Country Link
US (1) US8252820B2 (ru)
EP (1) EP1963293A1 (ru)
JP (1) JP2009518419A (ru)
KR (1) KR20080075218A (ru)
CN (1) CN101336235A (ru)
AR (1) AR058285A1 (ru)
AU (1) AU2006321902B2 (ru)
BR (1) BRPI0619567A2 (ru)
CA (1) CA2631007A1 (ru)
CR (1) CR10047A (ru)
EC (1) ECSP088509A (ru)
GT (1) GT200800093A (ru)
IL (1) IL191711A0 (ru)
MA (1) MA30018B1 (ru)
NO (1) NO20083030L (ru)
NZ (1) NZ568663A (ru)
PE (2) PE20100470A1 (ru)
RU (1) RU2008127262A (ru)
TN (1) TNSN08248A1 (ru)
TW (1) TW200800928A (ru)
UA (1) UA94921C2 (ru)
WO (1) WO2007067612A1 (ru)
ZA (1) ZA200804489B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008127253A (ru) * 2005-12-08 2010-01-20 Новартис АГ (CH) 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз
EP1963294B1 (en) * 2005-12-08 2012-10-10 Novartis AG 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
JP2009532379A (ja) * 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤
DE102007015169A1 (de) * 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2012027134A1 (en) * 2010-08-26 2012-03-01 Albemarle Corporation Processes for producing 1-bromo-2 (cyclopropyl methoxy)-5 fluoro-4- methoxybenzene
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012147516A1 (ja) 2011-04-28 2012-11-01 持田製薬株式会社 環状アミド誘導体
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2017078499A2 (ko) * 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
AU2019290197B2 (en) * 2018-06-21 2023-08-24 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
CN112739687B (zh) 2018-09-18 2025-07-04 巴斯夫欧洲公司 二氨基三嗪化合物
EP3938038A1 (en) * 2019-03-14 2022-01-19 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
EP4077291A1 (en) * 2019-12-18 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
US20240383886A1 (en) * 2019-12-20 2024-11-21 Calico Life Sciences Llc Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof
AU2021342161A1 (en) * 2020-09-11 2023-05-25 Abbvie Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
AU2022212381A1 (en) 2021-01-27 2023-08-10 Basf Se Diaminotriazine compounds
EP4305030A4 (en) * 2021-03-11 2025-05-21 Kumquat Biosciences Inc. HETEROCYCLES AND THEIR USES
WO2022261145A1 (en) * 2021-06-10 2022-12-15 Ness Therapeutics, Inc. Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
MX2024005656A (es) * 2021-11-11 2024-08-06 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
EP4430038A1 (en) * 2021-11-11 2024-09-18 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
AR128379A1 (es) 2022-01-31 2024-04-24 Bristol Myers Squibb Co Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
CA3243580A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics Inc TYROSINE PHOSPHATASE PROTEIN INHIBITORS AND THEIR USES
JP2025505994A (ja) * 2022-02-02 2025-03-05 ネリオ セラピューティクス，インク． プロテインチロシンホスファターゼ阻害剤およびその使用
JP2025507292A (ja) * 2022-02-02 2025-03-18 ネリオ セラピューティクス，インク． プロテインチロシンホスファターゼ阻害剤およびその使用
CN117658947A (zh) * 2022-09-06 2024-03-08 杭州中美华东制药有限公司 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物
EP4587436A1 (en) * 2022-09-13 2025-07-23 Kumquat Biosciences Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
JP2025539027A (ja) * 2022-11-09 2025-12-03 ブリストル－マイヤーズ スクイブ カンパニー タンパク質チロシンホスファターゼの阻害剤、組成物、および使用方法
AR131413A1 (es) * 2022-12-21 2025-03-19 Bristol Myers Squibb Co Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof
CN118852335A (zh) * 2023-04-28 2024-10-29 中科中山药物创新研究院 噻二唑烷酮衍生物及其制备方法和应用
WO2025011570A1 (zh) * 2023-07-11 2025-01-16 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
TW202519514A (zh) * 2023-07-14 2025-05-16 天主教魯汶大學 新穎化合物(一)
WO2025030008A1 (en) * 2023-08-02 2025-02-06 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitor combinations
WO2025055985A1 (zh) * 2023-09-15 2025-03-20 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN120004876A (zh) * 2023-11-16 2025-05-16 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用
CN119707953A (zh) * 2024-04-19 2025-03-28 中国药科大学 噻二唑烷酮衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076439A2 (en) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
US20040023974A1 (en) * 2002-04-03 2004-02-05 Coppola Gary Mark Cyclic sulfamide derivatives and methods of use
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
GB0227813D0 (en) 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
JP4611751B2 (ja) * 2002-12-30 2011-01-12 バーテックス ファーマシューティカルズ インコーポレイテッド 癌および自己免疫障害の処置のためのホスファターゼインヒビターとして使用するためのリン酸等価体としてのスルフヒダントイン
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
UA94724C2 (en) 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
RU2008127253A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз
EP1963294B1 (en) 2005-12-08 2012-10-10 Novartis AG 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト ＰＴＰａｓｅのチアジアゾリジノン阻害剤

Also Published As

Publication number Publication date
ECSP088509A (es) 2008-07-30
PE20100470A1 (es) 2010-07-13
ZA200804489B (en) 2009-08-26
JP2009518419A (ja) 2009-05-07
BRPI0619567A2 (pt) 2011-10-04
CR10047A (es) 2008-10-16
TNSN08248A1 (en) 2009-10-30
AU2006321902B2 (en) 2011-11-10
AU2006321902A1 (en) 2007-06-14
PE20071094A1 (es) 2008-01-07
GT200800093A (es) 2010-07-09
AR058285A1 (es) 2008-01-30
CA2631007A1 (en) 2007-06-14
US20100035942A1 (en) 2010-02-11
US8252820B2 (en) 2012-08-28
RU2008127262A (ru) 2010-01-20
WO2007067612A1 (en) 2007-06-14
CN101336235A (zh) 2008-12-31
IL191711A0 (en) 2008-12-29
TW200800928A (en) 2008-01-01
KR20080075218A (ko) 2008-08-14
MA30018B1 (fr) 2008-12-01
EP1963293A1 (en) 2008-09-03
NZ568663A (en) 2011-07-29
UA94921C2 (en) 2011-06-25

Similar Documents

Publication Publication Date Title
NO20083030L (no) 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer
NO20083031L (no) Tiadiazolderivater som anti-diabetiske agenter
TNSN08247A1 (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
WO2007115058A3 (en) Thiadiazolidinone inhibitors of ptpase
AR066820A1 (es) Compuestos de tiadiazolidin-3 ona
Liu et al. p53 modifications: exquisite decorations of the powerful guardian
BR0308974A (pt) Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b
Pellock et al. Gut microbial β-glucuronidase inhibition via catalytic cycle interception
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
WO2007149451A3 (en) Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
WO2008033562A3 (en) Kinase inhibitor compounds
EP1796669A4 (en) AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2006058064A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
NO20075731L (no) Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon
Mellini et al. Identification of diketopiperazine-containing 2-anilinobenzamides as potent sirtuin 2 (SIRT2)-Selective inhibitors targeting the “selectivity pocket”, substrate-binding site, and NAD+-Binding site
WO2007136640A3 (en) Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
WO2006055525A3 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
Zhao et al. Post-translational modifications of nuclear sirtuins
Santin et al. Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions
WO2006083970A3 (en) Tumor necrosis factor inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application